More Than A Magazine, A Movement
When it comes to the menopause and perimenopause landscape, many women are left navigating symptoms without clear, trustworthy information.
This conversation aims to change that—offering evidence-based insights, practical guidance and a broader look at the systemic reforms needed to improve menopause care.
Whether revisiting the early days of the women’s liberation movement or examining today’s most urgent debates, the Ms. magazine archive brings decades of reporting into conversation with the present moment.
In early February, while the nation was still reeling from the murders of Renee Good and Alex Pretti by federal agents, Loretta Ross and Jackson Katz—two feminist academics with decidedly different backgrounds and identities—discussed how U.S. federal agents became the enforcement arm of the nation’s racism and misogyny.
You’ll find this, and more, in the Spring 2026 issue of Ms.
Traveling this month? Keep your eyes peeled. For Women’s History Month, Ms. magazine is hitting the shelves at Hudson News airport bookstores across the country.
If you spot Ms. at Hudson News, snap a photo and tag @msmagazine on social media—we’d love to see it. Consider grabbing a copy for your flight; every purchase helps sustain our feminist journalism.
Mifepristone “works against endometriosis. It works against myoma [fibroids]. We are now involved in a study group that looks at whether it can prevent breast cancer,” says pioneering reproductive-health advocate Dr. Rebecca Gomperts. “It has so many potential uses, and it hasn’t been [developed].
“If we as women don’t make sure that it becomes available to meet our needs … then it won’t happen.”
This is the final installment of a new series, “The Moral Property of Women: How Antiabortion Politics Are Withholding Medical Care,” a serialized version of the Winter 2026 print feature article.
Across a range of conditions that disproportionately affect women, research into mifepristone’s potential has been slowed, defunded or blocked altogether. Nowhere is that clearer than in the treatment of endometriosis and other serious illnesses that leave millions of women in chronic pain.
Endometriosis—when endometrium cells grow outside the uterus—afflicts an estimated 10 percent of reproductive-age women. It can lead to chronic pelvic and back pain, heavy or abnormal bleeding, pain during sex or bowel movements, fatigue, bloating, digestive issues, infertility, anxiety and depression.
Mifepristone can help—it blocks the progesterone causing the cellular growth and decreases the size of existing endometrial lesions, thereby relieving painful symptoms. But antiabortion politics have obstructed the development of the medication for these uses in the U.S.
Researchers have also produced studies showing mifepristone is effective for treating ovarian and breast cancer, chronic inflammatory diseases, and several psychiatric disorders, including major depressive disorder, post-traumatic stress disorder (PTSD) and psychotic depression.
This is Part 2 of 3 in a new series, “The Moral Property of Women: How Antiabortion Politics Are Withholding Medical Care,” a serialized version of the Winter 2026 print feature article.
Despite mifepristone’s broad medical promise, its development has been repeatedly stymied by abortion opponents who fear wider availability would weaken their attempts to suppress abortion access.
More than 26 million women in the U.S. are affected by fibroids, which are noncancerous growths of the uterus that can reach the size of a grapefruit or larger. Treatment too often defaults to invasive surgery, either removing the fibroids or performing hysterectomies.
In China today, a three-month regimen of 10 milligrams of mifepristone per day is the approved protocol for treating fibroids. Meanwhile, American women still do not have access to this very effective nonsurgical treatment.
This is Part 1 of 3 in a new series, “The Moral Property of Women: How Antiabortion Politics Are Withholding Medical Care,” a serialized version of the Winter 2026 print feature article.
In a new bonus episode of Looking Back, Moving Forward, Ms. executive editor Kathy Spillar, consulting editor Carmen Rios, Ms. Committee of Scholars co-chair Janell Jobson, and legendary author, activist and professor Loretta Ross explore how the stories of our past can continue to inspire us—and give us hope in the fight forward.
“I don’t believe that the assault on women and women’s rights can be extracted from the overall dysfunction of all societies.”
“We have to keep rewriting history and reclaiming history, especially knowing that the forces out there are doing what they can to erase us.”
“There’s a long lineage of people who have been fighting this fight, because they know that we deserve justice.”
Mifepristone has shown potential to treat a striking range of diseases and conditions, some life-threatening: fibroids, breast cancer, depression, endometriosis, Gulf War illness and maybe even other autoimmune diseases, such as chronic fatigue syndrome and multiple sclerosis. Research also suggests that mifepristone may help prevent some forms of breast cancer and can serve as an effective weekly contraceptive without the side effects of hormonal birth control.
Yet despite the drug’s promise, its development has been repeatedly stymied by abortion opponents who fear wider availability would weaken their attempts to suppress abortion access.
The result? Women are left in needless pain and subject to invasive and unnecessary surgical procedures like hysterectomies.
Explore the 30 most popular articles published this year on MsMagazine.com—the articles feminists most clicked, shared, studied, bookmarked and passed out at marches.